A two-year multicenter, retrospective 'real world' clinical setting study on the efficacy and safety of a trabecular scaffold (Hydrus) combined with phacoemulsification

Session Details

Session Title: Glaucoma

Session Date/Time: Monday 09/10/2017 | 08:00-10:30

Paper Time: 09:24

Venue: Room 4.1

First Author: : A.Fea ITALY

Co Author(s): :    M. Rekas   L. Au                 

Abstract Details

Purpose:

To evaluate the efficacy and the safety of a novel trabecular bypass (Hydrus,Ivantis) combined with cataract surgery in a “real world” clinical setting Design: Retrospective, consecutive case series

Setting:

Dipartimento di Scienze Chirurgiche – Clinica Oculistica di Torino – Torino, Italy Department of Ophthalmology, Military Institute of Medicine, Warsaw, Poland Manchester Royal Eye Hospital, Central Manchester Foundation Trust, Manchester, UK

Methods:

Data on POAG patients who underwent a combined phacoemulsification and implant of the Hydrus (Ivantis) stent was analyzed. Data was collected pre-operatively and postoperatively through 24 months. Data included intraocular pressure (IOP), number of glaucoma medication (ngmeds), incidence of complications. Data were further analyzed considering patients with a pre-operative IOP<18 mmHg on meds and patients with IOP≥ 8 mm Hg.

Results:

92 eyes were included. Six patients had previous glaucoma surgeries. Mean baseline IOP was 19.4±4.4 mm Hg. Mean IOP was 15.5±2.7 mmHg, 15.7±2.5 mmHg at 1-2 years (p<0.001). The IOP drop was correlated to the baseline IOP (R2=0.72). The mean ngmeds (2.1) was significantly (p<0,001) reduced at one (0.6±1) and two years (0.7±1). 61% were medication free at two years. In patients with IOP≥18mmHg preoperatively the reduction of IOP and of ngmeds was higher. Two patients needed stent repositioning. One received Argon laser to unblock the stent and one patient underwent trabeculectomy.

Conclusions:

the Hydrus implantation combined with cataract surgery safely and effectively lowers the IOP and medication use in a “real world” clinical setting with results comparable to previous randomized clinical trials. Patients with IOP≥18mmHg pre-operatively had better results.

Financial Disclosure:

NONE